Hillevax, Inc. (HLVX)
$1.84
Live
Performance
- $1.84$1.88$1.84
0.27%
Downside
Day's Volatility :2.39%
Upside
2.13%
- $1.55$20.22$1.84
15.76%
Downside
52 Weeks Volatility :92.33%
Upside
90.9%
Returns
| Period | Hillevax, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -0.53% | 3.6% | 0.0% |
6 Months | -85.52% | 10.2% | 0.0% |
1 Year | -82.38% | 19.6% | 0.0% |
3 Years | -90.15% | 16.8% | -23.0% |
Highlights
Market Capitalization | 95.7M |
Book Value | $4.29 |
Earnings Per Share (EPS) | -3.38 |
Wall Street Target Price | 2.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.81% |
Return On Equity TTM | -73.77% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -141.7M |
Diluted Eps TTM | -3.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.47 |
EPS Estimate Next Year | -1.73 |
EPS Estimate Current Quarter | -0.78 |
EPS Estimate Next Quarter | -0.43 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 26.63%
Technicals Summary
Sell
Neutral
Buy
Hillevax, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Hillevax, Inc. | 4.44% | -85.52% | -82.38% | -90.15% | -90.15% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Hillevax, Inc. | NA | NA | NA | -2.47 | -0.74 | -0.32 | NA | 4.29 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Hillevax, Inc. | Buy | $95.7M | -90.15% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Hillevax, Inc.
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 164.7%
Institutional Holdings
Deerfield Management Co
8.04%T. Rowe Price Investment Management,Inc.
6.99%BlackRock Inc
4.20%Franklin Resources Inc
3.99%The Carlyle Group Inc
3.69%Deep Track Capital, LP
3.68%
Company Information
hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Organization | Hillevax, Inc. |
Employees | 90 |
CEO | Dr. Robert M. Hershberg M.D., Ph.D. |
Industry | Services |
